Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride use is linked to a lower risk of bladder cancer, especially in Caucasians and Hispanics.

Isoflavones may help with menopause symptoms but could be risky for women with hormone-sensitive cancers.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Some skin, hair, and nail supplements can be toxic, interact with medications, affect lab tests, and may increase cancer risk.

Certain genetic markers on the Y-chromosome may influence prostate cancer risk in Iraqi males.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

Prostaglandin E2 promotes skin cancer, but certain supplements and drugs may help reduce risk and improve treatment.

Bcl-2 helps hair regeneration but can also increase cancer risk.

Certain genetic markers may increase or decrease prostate cancer risk.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

ACTH-dependent Cushing's syndrome linked to metastatic cervical cancer is rare and has high risks.

Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.

The committee decided not to approve the drug due to low effectiveness and high risks.

A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

Older skin has higher cancer risk due to inflammation and stem cell issues.

Six new risk spots for early hair loss were found, which also link to Parkinson's disease and lower fertility. Two genes, FOXA2 and HDAC4, could be new treatment targets. Hair loss might also be connected to heart disease, metabolic syndrome, and prostate cancer.

Controlling cellular changes can enable safe rejuvenation without cancer risk.

Women with PCOS have a higher risk of diabetes, heart problems, certain cancers, and mental health issues, but early treatment can help manage these risks.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Women with PCOS face many health risks, but exercise, a healthy diet, and weight management can help.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.

Finasteride may reduce prostate cancer risk.

Finasteride and dutasteride might lower melanoma risk.